Venclexta (Wave 2) is the second in a multiwave series designed to track physician perception, uptake, and competitive environment regarding the newly launched chronic lymphocytic leukemia (CLL) drug, Venclexta (Roche/AbbVie’s venetoclax). Venclexta measures the impact of this novel agent on the relapsed/refractory CLL with del(17p) therapy market following launch, based on a blend of quantitative and qualitative primary research with U.S. hematologist-oncologists. This content evaluates physicians’ current awareness and perception of Venclexta relative to other currently available therapies for relapsed/refractory CLL, current and anticipated use of Venclexta, and promotional activity of Venclexta.

Questions answered:

  • What are the awareness of and familiarity with Venclexta among hematologist-oncologists?
  • What are the perceived clinical advantages and disadvantages of Venclexta compared with other marketed agents used for treating relapsed/refractory CLL?
  • To what extent is Venclexta currently being used by surveyed hematologist-oncologists? Where does Venclexta fit in the treatment algorithm? What reasons do nonprescribers give for not having prescribed Venclexta?
  • What promotional messages are being employed by Roche/AbbVie?


Market covered: United States.

Primary research: 75 hematologist-oncologists; qualitative interviews with 10 respondents.

Indication coverage: Relapsed/refractory CLL.

Table of contents

  • Venclexta Launch Tracking (US) Wave 2
    • Key Findings
    • Benchmarking Venclexta Launch Success vs. the Competition
      • Venclexta Experiences A Low Level of Use Among Physicians Compared with Other Benchmarking Agents
    • Prescriber and Nonprescriber Profiles
      • Who Is the Venclexta Prescriber?
    • Venclexta Awareness and Perceptions
      • Unaided and Aided Awareness of Venclexta
      • Familiarity with Venclexta
      • Sources of Familiarity with Venclexta
      • Initial Reaction to and Interest in Venclexta
        • Physicians Indicate a Moderate to High Level of Interest in Venclexta
      • Impressions of Venclexta
      • Prescriber and Nonprescriber Profiles
    • Venclexta Trial and Use
      • Willingness to Prescribe Venclexta
      • Number of Patients Currently Receiving Venclexta
      • Reasons for Not Yet Prescribing Venclexta
      • Anticipated Venclexta Use
      • Venclexta Performance on Key Attributes
    • Effectiveness of Face-to-Face Detailing for Venclexta
      • Venclexta Sales Representative Frequency and Reach
      • Satisfaction with Venclexta Sales Representative
      • Venclexta Message Recall
    • Methodology
      • Primary Market Research Methodology
    • Appendix
      • Abbreviations

Author(s): Dana Gheorghe

Dana Gheorghe, is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a in cellular biology and biochemistry from the University of Sheffield and a in Molecular Biology from the University of Edinburgh.

Related Reports

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Landscape & Forecast | Disease Landscape & Forecast

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) therapy market over th...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)

MARKET OUTLOOK Relapsed/refractory diffuse large B-cell lymphoma (R/R

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Epidemiology | Mature Markets Non-Hodgkin's Lymphoma

DRG Epidemiology’s coverage of non-Hodgkin’s lymphoma (NHL) comprises epidemiological estimat...

View Details

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Current Treatment | Detailed, Expanded Analysis (US)

Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of hematological malignancies that can be broadly classified into indolent and aggre...

View Details